… study analyzed experiences in treating a large population of NSCLC patients with gefitinib
and erlotinib in … We stratified all patients according to different lines of gefitinib or erlotinib. The …

… of six patients who benefited from erlotinib in our study … erlotinib may be more efficacious
than gefitinib on wild-type EGFR by higher-affinity binding to the EGFR kinase domain. Erlotinib …

… our lung cancer patients to compare the benefits derived from erlotinib and gefitinib and to
… We subsequently analyzed tumor tissue from a subgroup of these patients for a pilot study to …

… The present study identified no significant differences in efficacy or toxicity profile between
first-line erlotinib and gefitinib for patients with EGFR-mutant disease, and these results could …

… non-small cell lung cancer (NSCLC) patients in East Asia. The objective of this study was
to compare the efficacy of gefitinib and erlotinib in Taiwanese patients with advanced NSCLC. …

… , this study demonstrated that both gefitinib and erlotinib … study with inclusion of both
gefitinib and erlotinib in a properly conducted and powered phase III trial in an enriched patient …

… All patients in this study were included in the analysis of AEs. Comparisons … study will be
needed to validate our results. Currently, a phase III trial of gefitinib versus erlotinib for patients …

… II or III studies have proven the efficacy of gefitinib or erlotinib as … However, it is not clear
whether gefitinib or erlotinib has … of smokers and female patients, but the ISEL study (gefitinib vs. …

… The aim of the study was to compare the efficacies of EGFR‑TKIs in patients with common
(exon 19 deletions and exon 21 p.Leu858Arg) and rare EGFR mutations. A retrospective …

… with lung adenocarcinoma were randomly assigned to receive gefitinib or erlotinib. This
study aimed to investigate the noninferiority of gefitinib compared with erlotinib. The primary end …